US6036957A
(en)
*
|
1990-03-30 |
2000-03-14 |
Autoimmune, Inc. |
Suppression of T-cell proliferation using peptide fragments of myelin basic protein
|
US7090982B2
(en)
|
1991-10-22 |
2006-08-15 |
The Governors Of The University Of Alberta |
Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
|
US6252040B1
(en)
|
1991-10-22 |
2001-06-26 |
The Governors Of The University Of Alberta |
Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
|
US5800808A
(en)
|
1994-05-24 |
1998-09-01 |
Veda Research And Development Co., Ltd. |
Copolymer-1 improvements in compositions of copolymers
|
US5858964A
(en)
*
|
1995-04-14 |
1999-01-12 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
|
IL119989A0
(en)
*
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
WO1999041247A1
(en)
*
|
1998-02-13 |
1999-08-19 |
Autoimmune, Inc. |
TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
|
WO2000005249A2
(en)
|
1998-07-23 |
2000-02-03 |
The President And Fellows Of Harvard College |
Synthetic peptides and methods of use for autoimmune disease therapies
|
ES2527760T3
(es)
*
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
CA2337688C
(en)
|
1998-07-23 |
2016-04-05 |
Yeda Research And Development Co., Ltd. |
Treatment of autoimmune conditions with copolymer 1 and related copolymers
|
US6800287B2
(en)
*
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
JP4629229B2
(ja)
|
1998-09-25 |
2011-02-09 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッド |
分子量マーカーとして用いるため、また治療用途のための共重合体1関連ポリペプチド
|
WO2000020010A1
(en)
*
|
1998-10-02 |
2000-04-13 |
Yeda Research And Development Co., Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
US7083777B1
(en)
|
1999-04-02 |
2006-08-01 |
The Brigham And Women's Hospital, Inc. |
Immunomodulating polymers
|
AU780188B2
(en)
*
|
2000-01-20 |
2005-03-03 |
Yeda Research And Development Co. Ltd. |
The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
|
ZA200206457B
(en)
*
|
2000-02-18 |
2003-08-13 |
Yeda Res & Dev |
Oral, nasal and pulmonary dosage formulations of copolymer 1.
|
ATE329608T1
(de)
*
|
2000-02-18 |
2006-07-15 |
Yeda Res & Dev |
Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
|
EP1292279A4
(de)
*
|
2000-06-05 |
2005-01-12 |
Teva Pharma |
Verwendung von glatiramer acetat (copolymer 1) zur behandlung von störungen des zentralen nervensystems
|
US20020077278A1
(en)
*
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
CN100438906C
(zh)
*
|
2000-06-07 |
2008-12-03 |
耶达研究及发展有限公司 |
共聚物1和相关肽和多肽及其处理过的t细胞在保护cns细胞避免谷氨酸毒性中的用途
|
AU6887101A
(en)
*
|
2000-06-20 |
2002-01-02 |
Caprion Pharmaceuticals, Inc. |
Copolymers and methods of treating prion-related diseases
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
IL137460A0
(en)
|
2000-07-24 |
2001-07-24 |
Yeda Res & Dev |
Identifying antigen clusters for monitoring a global state of an immune system
|
US20040037828A1
(en)
|
2002-07-09 |
2004-02-26 |
Bar-Ilan University |
Methods and pharmaceutical compositions for healing wounds
|
SV2003000753A
(es)
|
2000-12-05 |
2003-06-16 |
Brigham & Womens Hospital |
Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
|
GB2369896A
(en)
|
2000-12-06 |
2002-06-12 |
Marconi Comm Ltd |
Tunable optical filter actuator
|
KR100442122B1
(ko)
*
|
2001-07-31 |
2004-07-30 |
한국전기연구원 |
영구 자석을 이용한 브러시리스 발전기
|
WO2003048735A2
(en)
|
2001-12-04 |
2003-06-12 |
Teva Pharmaceutical Industries, Ltd. |
Processes for the measurement of the potency of glatiramer acetate
|
AU2002353486B2
(en)
*
|
2001-12-06 |
2009-01-15 |
Yeda Research And Development Co. Ltd |
Vaccine and method for treatment of motor neurone diseases
|
EP1455826A2
(de)
*
|
2001-12-21 |
2004-09-15 |
Ilex Oncology, Inc. |
Kombination die anti-cd52 antikörper und sonstige therapeutische agenzien enthält zur behandlung von multipler sklerose
|
MXPA05007329A
(es)
|
2003-01-07 |
2005-09-30 |
Yeda Res & Dev |
Vacuna de gotas oculares que contiene copolimero 1 para inmunizacion terapeutica.
|
US8008258B2
(en)
*
|
2003-01-21 |
2011-08-30 |
Yeda Research And Development Co. Ltd. |
Cop 1 for treatment of inflammatory bowel diseases
|
WO2004091573A1
(en)
*
|
2003-03-04 |
2004-10-28 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
AU2004227852B2
(en)
|
2003-03-31 |
2010-01-14 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic immunomodulators for the treatment of asthma and allergy
|
JP2007509981A
(ja)
*
|
2003-10-31 |
2007-04-19 |
テバ ファーマシューティカル インダストリーズ リミティド |
薬物デリバリー用ナノ粒子
|
EP1684797A1
(de)
|
2003-11-12 |
2006-08-02 |
Yeda Research and Development Co. Ltd. |
Vakzine und verfahren zur behandlung von neurodegenerativen erkrankungen
|
DK1701730T3
(da)
|
2003-12-09 |
2013-11-25 |
Yeda Res & Dev |
Fremgangsmåde og vaccine omfattende copolymer 1 til behandling af psykiatriske forstyrrelser
|
AU2005211424A1
(en)
*
|
2004-02-02 |
2005-08-18 |
Mixture Sciences, Inc. |
Peptide mixtures with immunomodulatory activity
|
CA2558655A1
(en)
*
|
2004-03-01 |
2005-09-15 |
Kai W. Wucherpfennig |
Methods and compositions for treatment of autoimmune diseases
|
JP2007535498A
(ja)
*
|
2004-03-03 |
2007-12-06 |
テバ ファーマシューティカル インダストリーズ リミティド |
グラチラマー・アセテートおよびリルゾールでの併用療法
|
US20050260770A1
(en)
*
|
2004-04-01 |
2005-11-24 |
Cohen Irun R |
Antigen array and diagnostic uses thereof
|
JP5495490B2
(ja)
|
2004-05-07 |
2014-05-21 |
アレス トレーディング エスエイ |
ランダム共重合体を用いる疾患の治療方法
|
US7655221B2
(en)
*
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
US20060194725A1
(en)
*
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
CN101039691B
(zh)
|
2004-06-25 |
2013-07-31 |
魁北克益得生物医学公司 |
用于治疗神经疾病的组合物和方法
|
SI2361924T1
(sl)
*
|
2004-09-09 |
2014-04-30 |
Teva Pharmaceutical Industries Ltd. |
Postopek za pripravo zmesi trifluoroacetil glatiramer acetata ob uporabi očiščene bromovodikove kisline
|
HUE028833T2
(en)
*
|
2004-09-09 |
2017-01-30 |
Yeda Res & Dev |
Polypeptide mixtures, compositions containing them, process for their preparation, and applications
|
US8324641B2
(en)
*
|
2007-06-29 |
2012-12-04 |
Ledengin, Inc. |
Matrix material including an embedded dispersion of beads for a light-emitting device
|
JP5297653B2
(ja)
*
|
2004-10-29 |
2013-09-25 |
サンド・アクチエンゲゼルシヤフト |
グラチラマーの製造法
|
EP1827108B1
(de)
*
|
2004-11-29 |
2015-04-08 |
Yeda Research And Development Co., Ltd. |
Induktion der neurogenese und stammzellentherapie in kombination mit copolymer 1
|
AU2006211510B8
(en)
*
|
2005-02-02 |
2011-04-21 |
Teva Pharmaceutical Industries, Ltd. |
Process for producing polypeptide mixtures using hydrogenolysis
|
PL1848415T3
(pl)
*
|
2005-02-17 |
2013-10-31 |
Teva Pharma |
Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego
|
US20100167983A1
(en)
*
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
WO2006116602A2
(en)
*
|
2005-04-25 |
2006-11-02 |
Yeda Research And Development Company |
Markers associated with the therapeutic efficacy of glatiramer acetate
|
WO2007081975A2
(en)
*
|
2006-01-11 |
2007-07-19 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
US8206726B2
(en)
|
2006-02-06 |
2012-06-26 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic polysaccharides for promotion of immune system maturation and health
|
US8378072B2
(en)
|
2006-04-13 |
2013-02-19 |
Declion Pharmaceuticals, Inc. |
Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
|
EP2013628B1
(de)
|
2006-04-28 |
2016-01-06 |
Momenta Pharmaceuticals, Inc. |
Verfahren zur beurteilung von peptidmischungen
|
KR100831796B1
(ko)
*
|
2006-05-29 |
2008-05-28 |
엘지전자 주식회사 |
타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
|
US9089509B2
(en)
|
2006-06-28 |
2015-07-28 |
Yeda Research And Development Co., Ltd. |
Method of treatment of age-related macular degeneration
|
JP2009542864A
(ja)
*
|
2006-07-05 |
2009-12-03 |
モメンタ ファーマシューティカルズ インコーポレイテッド |
コポリマー1の調製のための改良法
|
EP2174130A2
(de)
|
2007-06-21 |
2010-04-14 |
Momenta Pharmaceuticals, Inc. |
Copolymer-testverfahren
|
US20090029766A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Lutnick Howard W |
Amusement gaming access and authorization point
|
EP2173766A1
(de)
*
|
2007-07-31 |
2010-04-14 |
Natco Pharma Limited |
Verfahren zur herstellung von glatirameracetat (copolymer-1)
|
NZ585367A
(en)
|
2007-10-16 |
2012-12-21 |
Peptimmune Inc |
Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
|
EP2217250A4
(de)
|
2007-11-09 |
2011-01-05 |
California Inst Of Techn |
Immunmodulierende verbindungen und relevante zusammensetzungen und verfahren
|
US20090149541A1
(en)
*
|
2007-11-28 |
2009-06-11 |
Yafit Stark |
Method of delaying the onset of clinically definite multiple sclerosis
|
RU2010146489A
(ru)
†
|
2008-04-16 |
2012-05-27 |
Момента Фармасьютикалз, Инк. (Us) |
Анализ композиций сополимера аминокислот
|
WO2010017292A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Scinopharm Taiwan, Ltd. |
Synthesis of glatiramer acetate
|
US8399600B2
(en)
*
|
2008-08-07 |
2013-03-19 |
Sigma-Aldrich Co. Llc |
Preparation of low molecular weight polylysine and polyornithine in high yield
|
AR074881A1
(es)
|
2008-12-24 |
2011-02-16 |
Synthon Bv |
Un proceso para purificar una mezcla de polimeros
|
US8859489B2
(en)
*
|
2009-04-03 |
2014-10-14 |
Momenta Pharmaceuticals, Inc. |
Water-mediated control of depolymerization step of glatiramer acetate synthesis
|
EP2438080B1
(de)
*
|
2009-06-04 |
2013-12-04 |
Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) |
Verfahren für die zubereitung von copolymer-1 (cop-1) aus l-alanin, l-lysin, l-glutaminsäure und l-tyrosin zur behandlung von multipler sklerose
|
PT2275086E
(pt)
|
2009-07-15 |
2012-05-18 |
Teva Pharma |
Formulação de volume reduzido de acetato de glatirâmero e métodos de administração
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
US8691790B2
(en)
*
|
2009-07-27 |
2014-04-08 |
James Layne Boucher |
Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
|
CA2876966A1
(en)
|
2009-08-20 |
2011-02-24 |
Yeda Research And Development Co., Ltd. |
Low frequency glatiramer acetate therapy
|
CN102686235A
(zh)
|
2010-01-04 |
2012-09-19 |
Mapi医药公司 |
包含格拉默或其药用盐的储药系统
|
US8377885B2
(en)
|
2010-01-04 |
2013-02-19 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
EP2523668A1
(de)
|
2010-01-13 |
2012-11-21 |
Ramot at Tel-Aviv University Ltd |
Behandlung multipler sklerose
|
US8759302B2
(en)
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
JP6027961B2
(ja)
|
2010-04-07 |
2016-11-16 |
シェン, ユエSHEN, Yue |
粘膜へ化合物を送るための媒体、それに関連する組成物、方法、及びシステム
|
AU2011248663A1
(en)
*
|
2010-04-27 |
2012-11-08 |
Dr. Reddy's Laboratories Ltd. |
Preparation of polypeptides and salts thereof
|
JP2013530949A
(ja)
|
2010-05-20 |
2013-08-01 |
エル ラウンド ジューン |
抗原特異的Treg並びに関連する組成物、方法及びシステム
|
CA2806997A1
(en)
*
|
2010-07-29 |
2012-02-02 |
Dr. Reddy's Laboratories Ltd. |
Glatiramer acetate molecular weight markers
|
BR112013008573A2
(pt)
|
2010-10-11 |
2016-07-12 |
Teva Pharma |
citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer.
|
WO2012123959A2
(en)
|
2011-02-14 |
2012-09-20 |
Usv Limited |
Copolymer-1, process for preparation and analytical methods thereof
|
ES2601892T3
(es)
|
2011-04-21 |
2017-02-16 |
Mapi Pharma Limited |
Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
|
WO2012150495A1
(en)
|
2011-05-05 |
2012-11-08 |
National Institute Of Immunology |
Synthetic peptides and random copolymers for the treatment of autoimmune disorders
|
WO2013009885A2
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Evaluation of copolymer diethylamide
|
WO2013009864A1
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Structure assessment of heterogeneous polypeptide mixtures
|
WO2013009945A1
(en)
|
2011-07-12 |
2013-01-17 |
The Brigham And Women's Hospital, Inc. |
Lipid-containing psa compositions, methods of isolation and methods of use thereof
|
US8575198B1
(en)
|
2011-09-07 |
2013-11-05 |
Momenta Pharmaceuticals, Inc. |
In-process control for the manufacture of glatiramer acetate
|
CN103957705A
(zh)
|
2011-10-10 |
2014-07-30 |
泰华制药工业有限公司 |
适用于预测对醋酸格拉替雷的临床反应的单核苷酸多态性
|
EP2642290A1
(de)
|
2012-03-19 |
2013-09-25 |
Synthon BV |
Potenztest basierend auf der humanen Glatiramer-Acetatmonzytzelllinie
|
WO2013139728A1
(en)
|
2012-03-19 |
2013-09-26 |
Synthon Bv |
Glatiramer acetate human monocyte cell-based potency assay
|
US20140045740A1
(en)
*
|
2012-08-13 |
2014-02-13 |
Momenta Pharmaceuticals, Inc. |
Analysis of glatiramer acetate
|
WO2014058976A2
(en)
|
2012-10-10 |
2014-04-17 |
Teva Pharmaceutical Industries Ltd. |
Biomarkers predictive for clinical response for glatiramer acetate
|
WO2014060942A2
(en)
*
|
2012-10-20 |
2014-04-24 |
Mahesh Kandula |
Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
|
WO2014128079A1
(en)
|
2013-02-19 |
2014-08-28 |
Synthon B.V. |
Glatiramer acetate multidose formulation
|
ES2529242T3
(es)
|
2013-03-08 |
2015-02-18 |
Teva Pharmaceutical Industries, Ltd. |
Dispositivo inyector reutilizable para jeringuilla
|
DK2774639T3
(en)
|
2013-03-08 |
2015-01-12 |
Teva Pharma |
Reusable injection device for a syringe
|
EP2971173A4
(de)
|
2013-03-14 |
2016-11-23 |
Mylan Inc |
Glatirameracetatreaktionsbiomarker-mrna-potenzassay
|
WO2014173463A1
(en)
|
2013-04-26 |
2014-10-30 |
Synthon Bv |
Glatiramer acetate human monocytic cell line-based potency assay
|
JP2016521284A
(ja)
|
2013-05-10 |
2016-07-21 |
カリフォルニア インスティチュート オブ テクノロジー |
大腸ガンのプロバイオティクスによる防止および処置
|
CN103265624B
(zh)
*
|
2013-05-27 |
2015-04-22 |
成都圣诺生物制药有限公司 |
格拉替雷的制备方法
|
CN104371012A
(zh)
*
|
2013-08-12 |
2015-02-25 |
深圳翰宇药业股份有限公司 |
一种合成醋酸格拉替雷的方法
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
CN105917001B
(zh)
*
|
2013-10-24 |
2020-11-20 |
迈兰公司 |
用于评估醋酸格拉替雷制品的免疫学同一性的人类t细胞系试验
|
WO2015101988A1
(en)
|
2013-12-31 |
2015-07-09 |
Yeda Research And Development Co. Ltd. |
Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
|
BR112016020919A2
(pt)
|
2014-03-12 |
2018-01-23 |
Yeda Res & Dev |
redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc
|
CN104844697B
(zh)
|
2014-09-26 |
2018-10-23 |
深圳翰宇药业股份有限公司 |
醋酸格拉替雷的制备方法
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|
WO2016139659A1
(en)
|
2015-03-01 |
2016-09-09 |
Immunarray Ltd. |
Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
|
WO2016201342A1
(en)
|
2015-06-10 |
2016-12-15 |
California Institute Of Technology |
Sepsis treatment and related compositions methods and systems
|
CN113637040A
(zh)
|
2015-08-19 |
2021-11-12 |
哈佛学院院长及董事 |
脂化psa组合物和方法
|
EP3147667B1
(de)
|
2015-09-24 |
2019-06-12 |
CHEMI S.p.A. |
Analyse der molekulargewichtsverteilung von komplexen polypeptidmischungen
|
EP3170836B1
(de)
|
2015-11-23 |
2018-10-24 |
Chemi SPA |
Rp-hplc-analyse komplexer polypeptidmischungen
|
CN107522774B
(zh)
*
|
2016-06-22 |
2021-07-02 |
深圳翰宇药业股份有限公司 |
一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
|
US20210220428A1
(en)
|
2016-06-30 |
2021-07-22 |
Stem Cell Medicine Ltd. |
Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
|
EP3484441A4
(de)
|
2016-07-15 |
2020-03-18 |
President and Fellows of Harvard College |
Glycolipidzusammensetzungen und verfahren zur verwendung
|
JP7232752B2
(ja)
|
2016-08-28 |
2023-03-03 |
マピ ファーマ リミテッド |
酢酸グラチラマーを含有する微小粒子を調製する方法
|
EP4252849A3
(de)
|
2016-08-31 |
2023-11-01 |
Mapi Pharma Ltd. |
Depotsysteme mit glatirameracetat
|
EP3600553A4
(de)
|
2017-03-26 |
2020-09-02 |
Mapi Pharma Ltd. |
Glatiramerdepotsysteme zur behandlung progressiver formen von multipler sklerose
|
IL269893B2
(en)
|
2017-05-15 |
2023-10-01 |
Stem Cell Medicine Ltd |
Treatment of multiple sclerosis using stem cells derived from adipose tissue
|
CA3062964A1
(en)
|
2017-05-15 |
2018-11-22 |
Stem Cell Medicine Ltd. |
Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
|
EP3765034A1
(de)
|
2018-03-12 |
2021-01-20 |
Yeda Research and Development Co. Ltd |
Behandlung einer herzkrankheit
|